-
公开(公告)号：US20230340067A1
公开(公告)日：2023-10-26
申请号：US18003093
申请日：2021-06-25
发明人： Stephen GOTTSCHALK , Giedre KRENCIUTE , Zelda ODE
IPC分类号： C07K14/705 , C07K14/725 , C07K14/73 , C12N5/0783 , C12N15/11 , C12N9/22 , C12N15/90
CPC分类号： C07K14/70521 , C07K14/7051 , C07K14/70514 , C07K14/70517 , C12N5/0636 , C12N15/11 , C12N9/22 , C12N15/907 , C07K2319/03 , C12N2310/20 , C12N2800/80
摘要： The present invention provides methods of genetically modifying an immune cell such that the immune cell expresses a transgene in an activation dependent manner. The application also provides genetically modified immune cells prepared using such methods, and the uses of the genetically modified immune cells in immunotherapy (e.g., adoptive cell therapy) for treatment of a disease such as cancer, autoimmune disease or infectious disease.
-
公开(公告)号：US20240216427A1
公开(公告)日：2024-07-04
申请号：US18270675
申请日：2021-12-29
IPC分类号： A61K35/17 , A61K39/00 , A61P35/02 , C07K14/705 , C07K14/725 , C07K16/18
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61P35/02 , C07K14/7051 , C07K14/70521 , C07K16/18 , A61K2239/13 , A61K2239/21 , C07K2317/565 , C07K2317/622 , C07K2319/02 , C07K2319/03
摘要： The application provides chimeric antigen receptors (CARs) that target splice variants of the extracellular matrix proteins tenascin C (TNC) and procollagen 11A1 (Col11A1), and their uses in tumor immunotherapy. The application also provides polynucleotides and vectors that encode the chimeric antigen receptors, as well as host cells comprising the chimeric antigen receptors. The application also provides methods for preparing host cells comprising the chimeric antigen receptors and methods for treating patients using the modified host cells.
-
公开(公告)号：US20230340040A1
公开(公告)日：2023-10-26
申请号：US17918644
申请日：2021-04-14
CPC分类号： C07K14/4702 , A61P35/00 , C12N15/63 , C07K2319/03
摘要： The present disclosure provides chimeric MyD88 receptors. Also provided are polynucleotides encoding the chimeric MyD88 receptors, vectors comprising the polynucleotides encoding the chimeric MyD88 receptors, and cell compositions comprising the chimeric MyD88 receptors, polynucleotides and/or vectors. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.
-
公开(公告)号：US20230312671A1
公开(公告)日：2023-10-05
申请号：US17919728
申请日：2021-04-23
发明人： Mireya Paulina VELASQUEZ , Stephen GOTTSCHALK , Nikhil HEBBAR , Rebecca EPPERLY , Abishek VAIDYA
IPC分类号： C07K14/725 , A61P35/00 , C12N15/63
CPC分类号： C07K14/7051 , A61P35/00 , C12N15/63 , C07K2319/02 , C07K2319/03
摘要： The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising at least one glucose-regulated-protein 78 (GRP78)-binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the host cells and methods for treating a tumor using the pharmaceutical compositions.
-
公开(公告)号：US20230030680A1
公开(公告)日：2023-02-02
申请号：US17791181
申请日：2021-01-06
发明人： Stephen GOTTSCHALK , Laurens SAND , Shannon LANGE
IPC分类号： C07K14/715 , A61K35/17
摘要： The present invention provides chimeric cytokine receptors, particularly chimeric cytokine receptors that canbe activated in tumor microenvironment, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The present invention further provides methods of genetically modifying therapeutic cells resulting in an enhanced immune response against a target antigen. The application further provides therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.
-
公开(公告)号：US20220226379A1
公开(公告)日：2022-07-21
申请号：US17602524
申请日：2020-04-08
IPC分类号： A61K35/17 , A61P35/02 , A61K35/545 , C12N9/10
摘要： The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.
-
公开(公告)号：US20230174653A1
公开(公告)日：2023-06-08
申请号：US17917198
申请日：2021-04-06
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , A61P35/00 , A61K35/17
CPC分类号： C07K16/2827 , A61K35/17 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70575 , C07K14/70578 , C07K2317/622 , C07K2319/02 , C07K2319/03
摘要： The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising a B7-H3 binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the isolated host cells and methods for treating a tumor using the pharmaceutical compositions.
-
公开(公告)号：US20220326216A1
公开(公告)日：2022-10-13
申请号：US17608079
申请日：2020-04-08
发明人： Benjamin YOUNGBLOOD , Jeremy CRAWFORD , Yiping FAN , Caitlin ZEBLEY , Stephen GOTTSCHALK , Giedre KRENCIUTE , Christopher PETERSEN
IPC分类号： G01N33/50 , C07K14/705 , A61K35/17
摘要： The application provides T cell gene expression signatures that can be used to predict T cell therapy outcomes.
-
公开(公告)号：US20220195007A1
公开(公告)日：2022-06-23
申请号：US17602892
申请日：2020-04-10
发明人： Mireya Paulina VELASQUEZ , Stephen GOTTSCHALK , Janice RIBERDY , Albert ZHOU , Byoung RYU , Abishek VAIDYA , Giedre KRENCIUTE
IPC分类号： C07K14/725 , A61P35/02 , C07K14/705 , C12N15/86 , C12N5/0783
摘要： The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have enhanced antitumor properties and/or can be regulated by safety switches. Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a cancer in a subject are also provided.
-
公开(公告)号：US20210252058A1
公开(公告)日：2021-08-19
申请号：US17056181
申请日：2019-05-17
IPC分类号： A61K35/17 , C07K14/705 , C07K14/725 , A61P35/00 , C07K16/28
摘要： The application relates to a chimeric antigen receptor that targets Eph receptors and allows activation of co-stimulatory pathways. The application also relates to polynucleotides that encode the chimeric antigen receptor, vectors, and host cells comprising the chimeric antigen receptor. The application also relates to methods for preparing host cells comprising a chimeric antigen receptor in order to improve the in vivo effector function of the chimeric antigen receptor host cells.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.022 秒)
